Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IGILUC 2019 /
First- and second-line treatments for locally advanced renal cell carcinoma

18th - 19th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.05.19
Views: 532
Rating:

Prof Jorge A. Garcia - Cleveland Clinic, Cleveland, USA

Prof Jorge Garcia speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about the various treatment options available for locally advanced renal cell carcinoma (RCC) patients in both the first-line and second-line setting.

Prof Garcia describes the historic use of targeted therapies such as tyrosine kinase and vascular endothelial growth factor inhibitors as the standard front-line choice of therapy for these patients.

For the second-line setting, he also states two agents (cabozantinib and nivolumab) which have both demonstrated a survival benefit for advanced RCC patients.

Over the last 18 months, Prof Garcia notes the utilisation of immuno-oncology agents in patients with untreated RCC during the front-line setting. In particular the use of the ipilimumab plus nivolumab regimen, which has become the standard of care in men with untreated, clear cell, metastatic RCC. However, this may change with encouraging data supporting the use of the pembrolizumab/axitinib regimen.

Prof Garcia concludes by stating the challenges clinicians face in the treatment of RCC, which include the absence of an effective biomarker which leads to the reliance of obsolete clinical features.
 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation